Loading…
← CockpitCompetitor Analysis › TDOC Teladoc Health, Inc.Open in the cockpit ↗

Teladoc Health, Inc.TDOCCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical/Nursing Services

Provider of virtual health care services, including telehealth visits, chronic condition management and mental health care.

Momentum leader 93
Mkt cap
$1.47B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$48.7M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-18.2 pp
WACC 11.2%
Hurdle
-25 pp
Req g minus delivered
Next earnings
97 days
23 Feb 2027
Close · USD$8.06
1D-5.1%
1W-9.8%
1M+29.8%
3M+24.2%
6M+24.4%
YTD+15.1%
1Y+19.4%
ATR %5.8%
Beta1.22
52w lowhigh18.5% off high

What Teladoc Health does

Provider of virtual health care services, including telehealth visits, chronic condition management and mental health care.

Integrated Care is sold to employers and health plans for a fixed monthly fee per enrolled member, with extra charges per visit, while BetterHelp sells therapy subscriptions straight to consumers who pay out of pocket and are won through heavy online advertising.

Products and services

  • General/urgent telehealth visits
  • Chronic condition management (Livongo)
  • Mental health (BetterHelp)

Customers

  • Health plan members
  • Employers
  • Individual consumers

Where it sits in the supply chain

  • Health care/telehealth
  • Virtual care platform
  • Telehealth visits, chronic care…

What could go right

  • Telehealth utilization growth
  • Chronic disease management contract wins

What could go wrong

  • Intensifying telehealth price competition
  • Goodwill impairment/profitability risk

Moat: narrow (scale, brand, data). Large telehealth user base and employer/health-plan contracts, though facing intensifying low-cost competition.

Headquarters: Purchase, New York · Founded: 2002 · Employees: 5,600

Named competitors

Teladoc Health at a glance

Size Teladoc Health (TDOC) is a United States Health Care company (Medical/Nursing Services) with a market value of $1.47B, the 1983rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $8.06 on 18 Nov 2026.

Performance Over six months the shares gained 24.4%, against +14.0% for the median peer and -2.2% for the United States market (cap-weighted) — 8th highest of 21 in its peer set.

Growth Revenue fell 2.4% over the last twelve months (peer median +9.2%); the operating margin is -5.4% (peer median 6.2%).

Valuation It trades at 0.7× enterprise value to sales against a peer median of 2.0× (3rd cheapest of 21).

Price implies For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -25 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 18.2 points below its cost of capital (11.2% WACC).

Credit Teladoc Health has 1 bond outstanding ($1.00B).

Short interest Short interest is 17.7% of the free float (30 Oct 2026).

Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026TDOC 123Peer median 111
Six months, rebased to 100: Teladoc Health against the median of its 20 peers (local-currency closes).

Teladoc Health financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$2.47B$2.53B$2.57B$2.60B$2.41B
Revenue growth—-2%-1%+8%—
Gross profit$1.32B$1.39B$1.44B$1.51B$1.41B
EBITDA$246M$213M$174M$141M$43.3M
Net income-$155M-$200M-$1.00B-$220M-$13.7B
Free cash flow$262M$281M$283M$339M$173M
Capital expenditure$142M$157M$124M$156M$173M
Total debt$1.04B$1.04B$1.58B$1.59B$1.59B

Quarterly statements and history in the cockpit →

Teladoc Health competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%0%+20%4544USPHAGLWGS1833AMBEASNDALMRIPSNLCLARIVIJAYADIA300244PNTGOPKMETROPOLISEMEISNUTXAGARWALEYETDOC6-month return →1-month return →
Up and to the right = strong over both horizons. Teladoc Health is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%0×5×10×15×4544USPHAGLWGS1833AMBEASNDAPSNLVIJAYADIA300244PNTGOPKMETROPOLISNUTX603882AGARWALEYETDOCRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Teladoc Health is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%0%100%200%4544USPH1833VIJAYAPNTGNUTXTDOCGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Teladoc Health is the large dot.

Teladoc Health competitors and peer comparison

Head to head with its named competitors (TDOC vs HIMS vs CVS)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Teladoc Health TDOC$1.47B+24%-2%-5%0.7×-6.4%
Hims & Hers Health HIMS$4.00B-26%+30%-1%1.7×n/a
CVS Health CVS$104B-13%+7%4%0.4×-3.8%

How Teladoc Health compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Teladoc Health against its 20 peers (data as of 18 Nov 2026)
MeasureTDOCPeer medianRank in peer set
1-month return+29.8%-0.3%2nd highest of 21
6-month return+24.4%+14.0%8th highest of 21
Distance from 52-week high-18.5%-23.8%8th highest of 21
Revenue growth (TTM)-2.4%+9.2%5th lowest of 21
Operating margin-5.4%6.2%5th lowest of 21
EV / Sales0.7×2.0×3rd cheapest of 21
Growth the price implies (Req g, 7 yrs)-6.4%8.5%2nd least demanding of 15
Growth delivered (Del g)+18.3%+9.5%5th highest of 15
Hurdle (Req g minus delivered)-24.6 pp+6.7 pp2nd least demanding of 15
ROIC minus cost of capital-18.2 pp-3.6 pp4th lowest of 20
EV / EBITDA6.7×20.0×2nd cheapest of 14
Net debt / EBITDA0.8×2.8×6th least indebted of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Teladoc Health TDOCUnited States$1.47B+24%-2%-5%0.7×-6.4%+18.3%
H.U.Group 4544.TJapan$1.44B+24%+1%3%1.0×9.7%+2.1%
U.S. Physical Therapy USPHUnited States$1.42B+53%+10%10%2.6×18.8%+13.0%
agilon health AGLUnited States$1.52B+12%+2%-2%0.2×n/an/a
GeneDx WGSUnited States$1.56B+16%+15%-14%3.5×n/an/a
Ping An Healthcare and Technology 1833.HKHong Kong$1.36B-47%+8%3%0.4×3.5%-5.1%
Ambea AMBEA.STSweden$1.59B+28%+11%9%1.7×1.1%+7.7%
Sonida Senior Living SNDAUnited States$1.59B-11%+70%-8%4.8×n/an/a
Lumexa Imaging LMRIUnited States$1.35B+89%+8%2%2.1×n/an/a
Personalis PSNLUnited States$1.62B+88%+17%-157%18.2×n/an/a
Clariane CLARI.PAFrance$1.32B-20%+1%6%1.6×6.8%+6.5%
Vijaya Diagnostic Centre VIJAYA.NSIndia$1.69B+18%+24%32%17.5×40.4%+16.7%
Diagnostyka DIA.WAPoland$1.28B-6%+19%15%2.5×7.3%+18.9%
Dian Diagnostics 300244.SZChina$1.70B+1%-5%9%1.4×0.3%-1.1%
Pennant PNTGUnited States$1.26B+1%+39%6%1.5×20.7%+19.4%
OPKO Health OPKUnited States$1.25B+37%-22%-29%2.8×n/an/a
Metropolis Healthcare METROPOLIS.NSIndia$1.25B+11%+20%18%6.5×32.4%+10.5%
Emeis EMEIS.PAFrance$1.78B-33%+4%3%1.6×21.2%+8.5%
Nutex Health NUTXUnited States$1.19B+42%-19%39%1.8×-18.0%+253.5%
Guangzhou Kingmed Diagnostics 603882.SSChina$1.86B+5%-3%7%1.9×5.4%-6.1%
Dr. Agarwal's Health Care AGARWALEYE.NSIndia$1.86B+20%+26%15%7.8×43.0%+26.9%

Teladoc Health bonds and credit

Teladoc Health has 1 bond outstanding with $1.00B face value.

Every bond, yield and spread in the cockpit →

Questions

Who are Teladoc Health's main competitors?
Named competitors: Amwell (private or unlisted), Hims & Hers Health (HIMS), CVS Health (CVS). The cockpit's measured peer set (industry) also includes H.U.Group (4544.T), U.S. Physical Therapy (USPH), agilon health (AGL), GeneDx (WGS), Ping An Healthcare and Technology (1833.HK), Ambea (AMBEA.ST).
Is Teladoc Health expensive compared with its peers?
On ev / sales it trades at 0.7× against a peer median of 2.0×, 3rd cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about -6% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -25 pp: the price already allows for a slowdown.
How has Teladoc Health stock performed?
Over six months to 18 Nov 2026 the shares returned +24.4% against +14.0% for the median peer; over one year +19.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.